SGLT2 inhibitors use tied to lower risk of kidney stones in patients with type 2 diabetes Medha Baranwal31 Jan 2024 11:15 AM ISTUSA: The use of SGLT2 inhibitors in adults with type 2 diabetes (T2D) may lower nephrolithiasis risk compared with GLP-1 receptor agonists or DPP4...
Two-step screening protocol can predict and prevent heart failure among adults with diabetes Dr. Kamal Kant Kohli5 Jan 2024 10:30 AM ISTUSA: In a recent study published in Circulation, the researchers have described a two-step screening protocol that combines clinical risk assessment...
SGLT-2 inhibitors promising option for CVD prevention in diabetes patients regardless of NAFLD status: JAMA Medha Baranwal3 Jan 2024 9:00 AM ISTSouth Korea: A recent study published in JAMA Network Open has highlighted the potential of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) as a...
Ipragliflozin tied to long-term reduction in BP in diabetes patients: PROTECT trial analysis Medha Baranwal6 Dec 2023 11:00 AM ISTJapan: A recent article published in Hypertension Research reports results from a sub-analysis of the PROTECT trial that shed light on the long-term...
Patients with lower BMI more likely to achieve target BP with SGLT2 inhibitors Medha Baranwal31 Oct 2023 10:15 AM ISTJapan: A paper published in Hypertension Research has suggested that pretreatment body mass index (BMI) affects the achievement of target blood...
SGLT2 inhibitors have similar fracture risk as other antidiabetics in postmenopausal women with diabetes: JAMA Medha Baranwal3 Oct 2023 11:15 AM ISTSouth Korea: A claims-based study involving two independent Korean cohorts revealed that SGLT2 inhibitors are associated with a lower or similar risk...
SGLT-2 inhibitors reduce gout flares and offer CV benefits among patients with type 2 diabetes and gout: Study Dr. Kamal Kant Kohli10 Aug 2023 11:15 AM ISTCanada: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) may reduce gout flares and cardiovascular events in patients with gout, a recent study...
Early introduction of SGLT2 Inhibitors attenuates association between dysglycaemia and CVD risk: Lancet Medha Baranwal29 Jun 2023 8:00 PM ISTItaly: Poor glycemic control in the first three years after diagnosis is associated with a subsequent increased risk of cardiovascular disease (CVD)...
SGLT2 inhibitors used less frequently in HFrEF patients despite potential CV benefits: JAMA Medha Baranwal24 May 2023 10:30 AM ISTUSA: A recent study published in JAMA Cardiology found low rates of SGLT2 inhibitors for HFrEF (heart failure with reduced ejection fraction) in the...
Are GLP1-Agonists best out of new diabetes medications for primary CVD prevention? Medha Baranwal10 May 2023 11:00 AM ISTUSA: Among diabetes patients already on insulin, metformin, or sulfonylurea treatment and without cardiovascular disease, the addition of GLP-1...
SGLT2 inhibitors use lowers cancer risk in patients with diabetes Medha Baranwal7 April 2023 11:30 AM ISTTaiwan: Patients with diabetes who receive sodium-glucose cotransporter-2 (SGLT2) inhibitors are at a significantly lower risk of cancer, a new study...
SGLT2 inhibitors reduce incident obstructive airway disease in type 2 diabetes patients Jacinthlyn Sylvia6 Feb 2023 8:00 PM ISTThe findings of a retrospective cohort study published in the Journal of American Medical Association suggests that type 2 diabetes patients in Hong...
